Medicus Advances Cancer Pipeline as Losses Widen
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) reported expanded Phase 2 data for its SkinJect skin cancer therapy and advanced development of its Teverelix prostate cancer program during the …
Medicus Advances Cancer Pipeline as Losses Widen Read More